Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Cerus Corp

CERS

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.

Last trade $1.91
Day change +$0.045 (+2.42%)
Day range $1.85 – $1.93
Volume 1,564,736
Market cap $376M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$375.63M
Price / earnings
—
Price / book
4.96×
Price / sales
1.49×
EV / sales
1.68×
EV / EBITDA
-565.02×

Profitability

Earnings per share
-$0.04
Return on assets
-3.57%
Return on equity
-9.66%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.84×
Current ratio
1.96×
Quick ratio
1.15×
Cash ratio
0.2×

Cash flow

Price / cash flow
107.42×
Price / free cash flow
760.39×
Free cash flow
$494K

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CERS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$64.02M$63.3M$59.89M$64.58M$60.24M$60.13M$48.85M$56.75M
Cost of revenue$27.45M$27.91M$25.77M$28M$24.56M$23.47M$17.82M$23.42M
Gross profit$36.57M$35.39M$34.13M$36.58M$35.68M$36.66M$31.04M$33.33M
Selling, general and administrative$21.92M$22.86M$19.95M$20.83M$18.62M$21.18M$20.29M$19.33M
Research and development$14.27M$14.39M$14.53M$16.39M$15.83M$18.9M$16.61M$15.44M
Total operating expenses$36.19M$37.25M$34.48M$37.22M$34.44M$40.08M$36.89M$34.78M
Operating income$383K-$1.86M-$354K-$641K$1.24M-$3.42M-$5.85M-$1.45M
Interest expense-$1.24M-$1.71M-$1.87M-$1.96M-$2.12M-$2.15M-$2.11M-$2.05M
Income before taxes-$514K-$2.89M-$1.56M-$2.07M$65K-$5.64M-$7.64M-$2.45M
Income taxes$66K$95K$91K$119K$85K$76K$74K$111K
Net income-$580K-$2.98M-$1.65M-$2.18M-$20K-$5.72M-$7.72M-$2.56M
Net income attributable to common shareholders-$550K-$2.94M-$1.64M-$2.18M-$19K-$5.71M-$7.72M-$2.52M
EBITDA$804K-$1.4M$93K-$248K$1.62M-$3.08M-$5.55M-$1.12M
Basic earnings per share$0.00-$0.01-$0.01-$0.01$0.00-$0.03-$0.04-$0.01
Diluted earnings per share$0.00-$0.01-$0.01-$0.01$0.00-$0.03-$0.04-$0.01

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Cerus: 3 Key Takeaways for Long-Term Investors

Cerus announced positive Phase III trial results for red blood cell pathogen reduction technology, a major market expansion opportunity. The company is shifting to higher-margin kit distribution for its fibrinogen complex product and achieved positive operating cash flow of $3 million. A partnership with Blood Centers of America is accelerating North American adoption, positioning the company toward GAAP profitability.

Benzinga

Perion Network Cuts Sales Outlook, Joins Range Resources And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures falling by around 10 points on Monday. Shares of Perion Network Ltd. (NASDAQ: PERI) fell sharply in today’s pre-market trading after the company slashed FY24 revenue guidance. Perion Network said it sees first-quarter revenue of $157 million, versus market estimates of $175.53 million. The company said it now expects FY24 revenue of $590 million to $610 million, versus prior outlook of $860 million to $880 million. Perion Network shares dipped 37.6% to $13.17 in pre-market ...

Benzinga

Cathie Wood's Ark Invest Sells Another Tranche Of Block Shares, Even As Bitcoin Price Stages A Recovery

On Wednesday, Cathie Wood-led Ark Invest made a significant move by offloading shares of Block Inc (NYSE:SQ) amidst Bitcoin (CRYPTO: BTC) prices recovering. The Block Inc Trade The sale, worth $3.5 million, was executed through Ark's flagship ARK Innovation ETF (NYSE:ARKK) and ARK Next Generation Internet ETF (NYSE:ARKW) with a total of 42,608 shares sold. The value of the trade, calculated from the latest closing price of $81.46. Notably, at the time of writing, Bitcoin traded nearly 6.6% higher at $67,330.71. Ark has sold Block shares in every trading session of the current week. On Monday, Ark sold Block shares worth $8.95 million and on Tuesday, the firm sold $7.5 million worth. For the week, ...Full story available on Benzinga.com

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.